Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

MLA

Liu, Zhigang, et al. “Neutralising Antibody Potency against SARS-CoV-2 Wild-Type and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease Treated with Infliximab and Vedolizumab after Three Doses of COVID-19 Vaccine (CLARITY IBD): An Analysis of a Prospective Multicentre Cohort Study.” The Lancet Gastroenterology & Hepatology, vol. 8, no. 2, Feb. 2023, pp. 145–56. EBSCOhost, https://doi.org/10.1016/S2468-1253(22)00389-2.

APA

Liu, Z., Le, K., Zhou, X., Alexander, J. L., Lin, S., Bewshea, C., Chanchlani, N., Nice, R., McDonald, T. J., Lamb, C. A., Sebastian, S., Kok, K., Lees, C. W., Hart, A. L., Pollok, R. C., Boyton, R. J., Altmann, D. M., Pollock, K. M., Goodhand, J. R., … Bishop, J. (2023). Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. The Lancet Gastroenterology & Hepatology, 8(2), 145–156. https://doi.org/10.1016/S2468-1253(22)00389-2

Chicago

Liu, Zhigang, Kaixing Le, Xin Zhou, James L Alexander, Simeng Lin, Claire Bewshea, Neil Chanchlani, et al. 2023. “Neutralising Antibody Potency against SARS-CoV-2 Wild-Type and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease Treated with Infliximab and Vedolizumab after Three Doses of COVID-19 Vaccine (CLARITY IBD): An Analysis of a Prospective Multicentre Cohort Study.” The Lancet Gastroenterology & Hepatology 8 (2): 145–56. doi:10.1016/S2468-1253(22)00389-2.